Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS

Fig. 5

AMD3100 administration had little effect on 70- and 90-day-old SOD1G93A mice survival and disease onset. a Survival of mice treated with AMD3100 (n = 10) and PBS (n = 7) at 70 days old. Mantel-Cox test; p = 0.0025. b Disease onset of mice treated at 70 days old. c Survival of mice treated with AMD3100 (n = 9) and PBS (n = 10) at 90 days old. d Disease onset of mice treated at 90 days old

Back to article page